Elicio Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview

Elicio Therapeutics

13/03/2024 20:06

* Elicio Therapeutics Inc  ELTX.OQ   ELTX.O  is expected
to show
no change in quarterly revenue when it reports  results on March
15 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Elicio Therapeutics Inc
is for
a loss of 78 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Elicio
Therapeutics Inc is $11.00​, above​ its last closing price
of $5.48. ​​​

This summary was machine generated March 13 at 20:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)